In this interview, we speak with Cecile Riviere-Cazaux, an MD PhD candidate whose work bridges neurosurgery, clinical oncology, and multiomics to advance brain tumor research. Her focus lies in developing liquid biopsy techniques—using plasma, cerebrospinal fluid, and microdialysis—to improve monitoring and treatment response assessment in glioma patients. We explore the challenges of current imaging and biopsy methods, the promise of metabolomics and multiomics integration, and how these approaches could complement traditional diagnostics. Cecile Riviere-Cazaux also shares insights on translating these technologies into clinical practice and the future of personalized cancer care.